

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden

hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001624422			Corporation
Name of Issuer			Limited Partnership
Erytech Pharma			X Limited Liability Company
Jurisdiction of Incorporation/Organization			General Partnership
FRANCE			Business Trust
Year of Incorporation/Organization			Other (Specify)
X Over Five Years Ago			
Within Last Five Years (Specify Year)			
Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name of Issuer	Street Address 1	Street Address 2	City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Erytech Pharma	60 AVENUE ROCKEFELLER		LYON	FRANCE	69008	011-33-4-78-74-44-38

3. Related Persons

Last Name	First Name	Middle Name	Street Address 1	Street Address 2	City	State/Province/Country	ZIP/PostalCode
BEYEN	Gil		3 Place des Celestins		LYON	FRANCE	69002
Relationship: X Executive Officer Director Promoter							

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name	Street Address 1	Street Address 2	City	State/Province/Country	ZIP/PostalCode
GOINEAU	Pierre-Olivier		7 Rue Sala		LYON	FRANCE	69002
Relationship: Executive Officer X Director Promoter							

Clarification of Response (if Necessary):

Chief Operating Officer

Last Name	First Name	Middle Name
GODFRIN	Yann	
Street Address 1	Street Address 2	
23 Rue Henri Gorjus		
City	State/Province/Country	ZIP/PostalCode
LYON	FRANCE	69005
Relationship:	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

Chief Scientific Officer

Last Name	First Name	Middle Name
BAILLY	J?r?me	
Street Address 1	Street Address 2	
5 Rue Benoit Berlioz		
City	State/Province/Country	ZIP/PostalCode
CHASSIEU	FRANCE	69680
Relationship:	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

Managing member and Qualified Person

Last Name	First Name	Middle Name
BRYAN GARNIER & CO	None	
Street Address 1	Street Address 2	
53 Chandos Place		
City	State/Province/Country	ZIP/PostalCode
LONDON	UNITED KINGDOM	WC2N 4HS
Relationship:	Executive Officer	Director X Promoter

Clarification of Response (if Necessary):

Company acting as Global co-ordinator and bookrunner

Last Name	First Name	Middle Name
LifeSci Capital	None	
Street Address 1	Street Address 2	
250 West 55th Street	Suite 16B	
City	State/Province/Country	ZIP/PostalCode
NEW YORK	NEW YORK	NY 10019
Relationship:	Executive Officer	Director X Promoter

Clarification of Response (if Necessary):

Company acting as co-lead US placement agent

4. Industry Group

Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	Computers
Investing	Pharmaceuticals	Telecommunications
Investment Banking	Other Health Care	Other Technology
Pooled Investment Fund		

Is the issuer registered as an investment company under the Investment Company Act of 1940?

Yes No

Other Banking & Financial Services

Business Services

Energy

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

Manufacturing

Real Estate

Commercial

Construction

REITS & Finance

Residential

Other Real Estate

Travel

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
X No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
Rule 505	Section 3(c)(5)	Section 3(c)(13)
X Rule 506(b)	Section 3(c)(6)	Section 3(c)(14)
Rule 506(c)	Section 3(c)(7)	
Securities Act Section 4(a)(5)		

7. Type of Filing

X New Notice Date of First Sale 2014-10-24 First Sale Yet to Occur

Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity

Debt

Option, Warrant or Other Right to Acquire Another Security

Security to be Acquired Upon Exercise of Option, Warrant or

Pooled Investment Fund Interests

Tenant-in-Common Securities

Mineral Property Securities

X Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number <input checked="" type="checkbox"/> None	
BRYAN GARNIER & CO	None	
(Associated) Broker or Dealer <input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number	<input checked="" type="checkbox"/> None
None	None	
	Street Address 1	Street Address 2
53 Chandos Place		
City	State/Province/Country	ZIP/Postal Code
LONDON	UNITED KINGDOM	WC2N 4HS
State(s) of Solicitation (select all that apply)		
Check "All States" or check individual States	<input checked="" type="checkbox"/> All States	<input checked="" type="checkbox"/> Foreign/non-US

Recipient	Recipient CRD Number <input checked="" type="checkbox"/> None	
LifeSci Capital	None	
(Associated) Broker or Dealer <input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number	<input checked="" type="checkbox"/> None
None	None	
	Street Address 1	Street Address 2
250 West 55th Street	Suite 16B	
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	NY 10019
State(s) of Solicitation (select all that apply)		
Check "All States" or check individual States	<input checked="" type="checkbox"/> All States	<input type="checkbox"/> Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount USD or Indefinite

Total Amount Sold \$37,232,686 USD

Total Remaining to be Sold USD or Indefinite

Clarification of Response (if Necessary):

The total amount sold in the USA under exemption and in Europe is exactly of a total of 29,999,980.50 euros

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

33

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$1,781,648 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

The exact amount is 1,434,999 euros

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$1,781,648 USD Estimate

Clarification of Response (if Necessary):

The exact amount is 1,435,358 euros and concerns promoters.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Erytech Pharma	Gil BEYEN	Gil BEYEN	Chief Executive Officer	2014-11-07

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

